Back to search

Peptide record

TPDB40742

PTPRJ-pep19.3 Anticancer standard
9 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB40742
PTPRJ-pep19.3
Anticancer
Cancer-related peptides
AntiCP 2.0 CancerPPD 2.0 Peptipedia SATPdb dbACP iACP-DRLF
standard
No
A 9-aa standard natural anticancer peptide sequence curated from AntiCP 2.0, CancerPPD 2.0, Peptipedia, and other sources, with an available 3D structural model.
Sequence
CHANLTHAC
Physicochemical Analysis
C38H60N14O12S2
RDEQGIKMFPSWYV
ACH
969.10
7.16
2
0
3
+0
1.10
0.200
65.56
Mammalian: 1.2 hour Yeast: >20 hour E.coli: >10 hour
125
12.90
4
Residue Composition
number
2
A
0
R
1
N
0
D
2
C
0
E
0
Q
0
G
2
H
0
I
1
L
0
K
0
M
0
F
0
P
0
S
1
T
0
W
0
Y
0
V
Amino Acid Distribution
A: 2 R: 0 N: 1 D: 0 C: 2 E: 0 Q: 0 G: 0 H: 2 I: 0 L: 1 K: 0 M: 0 F: 0 P: 0 S: 0 T: 1 W: 0 Y: 0 V: 0
Chemical Descriptors
9
C38H60N14O12S2
969.10
7.16
+0
1.10
0.200
Free
L
Cyclic(C1-C9)
Free
Anticancer
PTPRJ agonist peptides
Evidence Records 3 records
Evidence 1 Activity

Activity

28 ± 5.5% cell growth inhibition at 160 µM in 24 hours
Anticancer

Target

Cervical Cancer
HeLa
Cervix

Assay & Model

Trypan blue assay
24-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2013

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

46 ± 4.2% cell growth inhibition at 160 µM in 48 hours
Anticancer

Target

Cervical Cancer
HeLa
Cervix

Assay & Model

Trypan blue assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2013
Evidence 3 Activity

Activity

51 ± 1.4% cell growth inhibition at 160 µM in 72 hours
Anticancer

Target

Cervical Cancer
HeLa
Cervix

Assay & Model

Trypan blue assay
72-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2013